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Imperial College London, London, UKIntroduction: IgA nephropathy (IgAN) is characterized by glomerular deposition of galactose-deﬁcient
IgA1 and complement proteins and leads to renal impairment. Complement deposition through the
alternative and lectin activation pathways is associated with renal injury.
Methods: To elucidate the contribution of the lectin pathway to IgAN, we measured the 11 plasma lectin
pathway components in a well-characterized cohort of patients with IgAN.
Results: M-ﬁcolin, L-ﬁcolin, mannan-binding lectin (MBL)–associated serine protease (MASP)-1 and MBL-
associated protein (MAp) 19 were increased, whereas plasma MASP-3 levels were decreased in patients
with IgAN compared with healthy controls. Progressive disease was associated with low plasma MASP-3
levels and increased glomerular staining for C3b/iC3b/C3c, C3d, C4d, C5b-9, and factor H–related protein 5
(FHR5). Glomerular FHR5 deposition positively correlated with glomerular C3b/iC3b/C3c, C3d, and C5b-9
deposition, but not with glomerular C4d. These observations, together with the ﬁnding that glomerular
factor H (fH) deposition was reduced in progressive disease, are consistent with a role for fH deregulation
by FHR5 in renal injury in IgAN.
Conclusion: Our data indicate that circulating MASP-3 levels could be used as a biomarker of disease
severity in IgAN and that glomerular staining for FHR5 could both indicate alternative complement
pathway activation and be a tissue marker of disease severity.
Kidney Int Rep (2018) 3, 426–438; https://doi.org/10.1016/j.ekir.2017.11.015
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license (http://creativecommons.org/licenses/by/4.0/).I gA nephropathy (IgAN) is a common glomerular pa-thology that frequently causes renal failure, especially
in young people.1,2 IgAN is characterized by glomerular
deposits of galactose-deﬁcient IgA1.3,4 Although a 4-hit
theory is proposed for mesangial IgA deposition,5 the
mechanisms leading to glomerular injury remain poorly
understood. The clinical course of IgAN is heteroge-
neous: after 20 years of follow-up from renal biopsy,
up to 40% of patients will reach end-stage renal disease,spondence: Matthew C. Pickering, Centre for Complement
ﬂammation Research, Imperial College London, Hammer-
Campus, Du Cane Road, London W12 0NN, UK. E-mail:
ew.pickering@imperial.ac.uk
ved 26 October 2017; revised 16 November 2017; accepted
vember 2017; published online 29 November 2017but 20% of patients will have preserved renal function.6
Our incomplete understanding of IgAN pathogenesis
limits the development of biomarkers allowing the iden-
tiﬁcation of patients who may beneﬁt from immunosup-
pression and disease-speciﬁc therapies.2,7
The complement system is an important
inﬂammation-generating arm of the immune system.
Complement activation occurs in IgAN.8 Colocalization
of glomerular complement C3c with IgA is present in
90% of cases.3 Serum levels of activated C39 and
mesangial C3 deposition10 correlate with loss of renal
function. The degree of complement regulation is also
important. Imbalances in plasma factor H (fH), an
essential negative regulator of C3 activation, and factor
H–related (FHR) proteins 1 and 5, that deregulate fH,Kidney International Reports (2018) 3, 426–438
NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severity CLINICAL RESEARCHassociate with IgAN.11,12 Complement activation leads to
the accumulation of C3 proteolytic fragments, such as
C3dg, within glomeruli.8
The lectin pathway pattern-recognition molecules
include MBL (mannan-binding lectin), L-ﬁcolin (also
called ﬁcolin-2), M-ﬁcolin (ﬁcolin-1), H-ﬁcolin (ﬁcolin-3),
collectin liver 1 (CL-L1, also called CL-10), and collectin
kidney 1 (CL-K1 or CL-11). Following interaction with
ligands that include pathogen and/or damage-
associated molecular patterns, the pattern-recognition
molecules trigger complement activation through
complexed serine proteases: MBL-associated serine
protease (MASP)-1, MASP-2, and MASP-3. Pattern-
recognition molecules also can bind nonenzymatic
subunits: MBL-associated protein (MAp) 19 and
MAp44. The pathway generates a C3-convertase,
termed C4bC2b.13 The C4b is further processed to C4d.
The ﬁnding of glomerular C4d in the absence of C1q,
the activator of the classic pathway of complement, in
IgAN is consistent with lectin pathway activation.14
IgAN is characterized by disease ﬂares following
respiratory or gastrointestinal tract inﬂammation15;
both IgA and the lectin complement pathway are
important mediators of innate immunity at these sites.
IgAN is associated with higher levels of IgA1 with
exposed N-acetyl-galactosamine.5,16 N-acetyl-galactos-
amine is a structure that may trigger lectin pathway
activation due to interaction of ﬁcolins with patterns of
acetyl-groups.17 Furthermore, MBL binds polymeric
IgA and triggers complement activation in vitro.18 Both
high and very low MBL levels were associated with
poor renal outcomes in a Chinese IgAN population.19
Roos et al.20 demonstrated glomerular MBL, L-ﬁcolin,
MASP1/3, and C4d deposition in 25% of patients with
IgAN, which associated with disease severity. This
ﬁnding is supported by the association of glomerular
C4d deposition with poor prognosis in IgAN.12,21
We hypothesized that the lectin pathway contrib-
utes to glomerular inﬂammation and disease severity in
IgAN. We examined (i) levels of circulating lectin
pathway components; (ii) glomerular complement
deposition; and (iii) glomerular fH, FHR1, and FHR5
deposition in IgAN. Using a cohort of patients with
IgAN stratiﬁed into those with either stable or pro-
gressive disease, we identiﬁed circulating lectin
pathway components, glomerular complement protein
deposition, and immunohistologic evidence of fH
deregulation that correlated with disease severity.METHODS
Study Cohort and Clinical Measurements
We expanded our previously characterized11 Causes and
Predictors of Outcome in IgANephropathy study cohortKidney International Reports (2018) 3, 426–438of patients with biopsy-proven IgAN to 323 patients
(Supplementary Figure S1, UK National Research Ethics
Service Committee number 14/LO/0155). Progressive
disease was deﬁned by at least 1 of the following criteria:
(i) end-stage renal disease without histology evidence of
a second pathology causing renal impairment; (ii) biopsy
evidence of endocapillary hypercellularity, or (iii)
cellular and/or ﬁbrocellular crescents; (iv) treatment
with immunosuppression for native IgAN; (v) clinical
Henoch-Schonlein purpura, unless spontaneous resolu-
tion and>20 years of follow-upwith “stable” criteria; or
(vi) 50% loss of estimated glomerular ﬁltration
rate (eGFR) or average annual loss of eGFR of more than
5 ml/min without evidence of a second pathology
causing renal impairment. Stable disease was deﬁned as
meeting all of the following: (i) urine protein-creatinine
ratio less than 100 units or daily proteinuria of less than 1
g/24 hours; (ii) combined Oxford classiﬁcation22 MEST
(mesangial hypercellularity [M], endocapillary hyper-
cellularity [E], segmental glomerulosclerosis [S], inter-
stitial ﬁbrosis/tubular atrophy [T]) score of less than 3;
and (iii) average annual loss of eGFR of less than 3ml/min
per 1.73 m2. The transplantation cohorts have also been
characterized.11 Control samples were obtained from
healthy volunteers. The eGFR was calculated using the
Chronic Kidney Disease Epidemiology Collaboration
Creatinine Equation.23
Protein Measurements
Levels of MBL,24 M-ﬁcolin,25 H-ﬁcolin,26 CL-L1,27
CL-K1,28 MASP-1,29 MASP-2,30 MASP-3,31 MAp19,32
and MAp4431 were measured using time-resolved
immunoﬂuorometric sandwich-type immunoassays as
previouslydescribedusing“in-house” antibodies. Plasma
L-ﬁcolin was measured by enzyme-linked immunosor-
bent assay (Hycult Biotech, Uden, The Netherlands).
Serum IgA and galactose-deﬁcient IgA1 levels were
measured by enzyme-linked immunosorbent assay.33
Histology
Immunohistochemistry protocols were optimized
(Supplementary Figures S2–S4) for formalin-ﬁxed
parafﬁn-embedded renal biopsy tissue with the
following antibodies: rabbit polyclonal anti-human C3c
(Dako, Glostrup, Denmark), rabbit polyclonal anti-
human C4d (DB Biotech, Kosice, Slovakia), mouse
monoclonal anti-human factor H (OX-24; Abcam,
Cambridge, UK), rabbit polyclonal anti-human C3d
(Abcam), mouse monoclonal anti-human C5b9 (Dako),
mouse monoclonal anti-human FHR1 (Abnova, Taipei,
Taiwan), and rabbit polyclonal anti-human FHR5
(Abnova). The anti-C3c antibody cannot distinguish
among C3c, C3b, and iC3b, so we refer to this staining
as anti-C3b/iC3b/C3c. We graded antigen-staining427
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CLINICAL RESEARCH NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severityintensities from anonymized sections as 0 (absent), 0.5
(minimal), 1þ, 2þ, and 3þ. Staining described as
“positive” includes 1þ, 2þ, and 3þ. Staining
described as “negative” includes 0 and 0.5. For tubular
cell FHR1 staining, we used the area of most intense
staining to grade tubular cell FHR1 staining intensity
from 0 to 3. We identiﬁed 41 IgAN biopsies with me-
dian of 6 glomeruli per section (range 2–16). All bi-
opsies had absent or nonsigniﬁcant C1q staining
documented in clinical reports. We excluded sections
that contained <2 nonsclerosed glomeruli.
Statistical Analysis
Analyses were performed using GraphPad Version 6.00
for Windows (La Jolla, CA). Normally distributed
continuous variables were compared using unpaired or
paired t-test and 1-way analysis of variance for multi-
ple groups. Continuous variables with skewed distri-
bution were tested using Mann-Whitney U tests,
Kruskal-Wallis tests for multiple groups, and Wil-
coxon matched-pairs signed rank test for matched
transplant samples. Conﬁdence intervals (CIs) were
calculated using the Hodges-Lehmann method; cate-
gorical data compared using the Fisher exact test; and
correlation assessed using Pearson or Spearman rank
tests. We adjusted for multiple analyses with the 2-
stage linear step-up procedure of Benjamini, Krieger,
and Yekutieli.34
RESULTS
Plasma M-Ficolin, L-Ficolin, MASP-1, and
MAp19 Are Increased, Whereas Plasma MASP-3
Levels Are Reduced in IgAN
Due to the large number of cases and lectin proteins, we
quantiﬁed lectin pathway plasma concentrations in 2
stages. In the assessment cohort of 125 patients with
IgAN and 211 controls, we measured the plasma con-
centrations of MBL, MASP-1, MASP-2, MASP-3,
MAp19, MAp44, CL-K1, CL-L1, M-ﬁcolin, H-ﬁcolin,
and L-ﬁcolin (Table 1). We found plasma levels of M-
ﬁcolin, L-ﬁcolin, MASP-1, and MAp19 were increased,
whereas MASP-3 levels were reduced in patients. This
was conﬁrmed in our entire patient cohort (n ¼ 323,
Table 1). The difference in MBL level seen in the
assessment cohort between white patients with IgAN
and healthy controls was not replicated. The proportion
of MBL-deﬁcient individuals (plasma
concentration <100 ng/ml) did not differ between pa-
tients and controls (Table 1). Notably, as the 2 proteins
are alternative splice products from the same gene
(MASP-2), 1 patient had a very low plasma MAp19 level
(<65 ng/ml) but normal plasma MASP-2 level (180 ng/
ml). M-ﬁcolin is expressed in peripheral blood leuco-
cytes.35 There was a positive correlation between plasma428 Kidney International Reports (2018) 3, 426–438
NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severity CLINICAL RESEARCHM-ﬁcolin and white cell count (r ¼ 0.38, P < 0.0001;
Supplementary Figure S5). However, 93% of our cohort
had a white cell count in the normal range. L-ﬁcolin,
MASP-1, MAp19, and MASP-3 are expressed by hepa-
tocytes.13 We identiﬁed a positive correlation between
plasma MASP-3 and alanine aminotransferase (r ¼ 0.31,
P¼ 0.0015; Supplementary Figure S5), a marker of liver
inﬂammation. No associations were identiﬁed between
alanine aminotransferase and plasma L-ﬁcolin, MASP-1,
or MAp19 concentrations (data not shown). Plasma
MASP-3 levels did not correlate with proteinuria
(Supplementary Figure S5).
Plasma M-Ficolin and MAp19 Levels Are
Inﬂuenced by Glomerular Filtration Rate
There was no relationship between eGFR and plasma
levels of either L-ﬁcolin or MASP-1 (Supplementary0
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Figure 1. Plasma lectin pathway components in IgA nephropathy. (a) Plasm
3 (left), M-ﬁcolin (middle), and MBL-associated protein (MAp) 19 (right) in
Mann-Whitney test. (b) Plasma MASP-3 (left), M-ficolin (middle), and MAp
reduced (<30 ml/min) estimated glomerular filtration rate (eGFR) and healt
MASP-3 (left), M-ficolin (middle), and MAp19 (right) before and after re
autosomal dominant polycystic kidney disease (ADPKD, gray circles). P v
Kidney International Reports (2018) 3, 426–438Figure S6). Plasma MASP-3 levels positively correlated
(r ¼ 0.29, P < 0.0001), whereas M-ﬁcolin and MAp19
negatively correlated with eGFR (r ¼ 0.17, P ¼ 0.002
and r ¼ 0.13, P ¼ 0.02, respectively; Supplementary
Figure S6). Increased plasma M-ﬁcolin and MAp19,
and reduced MASP-3 levels, were still evident when we
compared patients with preserved eGFR (>60 ml/min)
with healthy controls (Figure 1b). These differences
increased in magnitude when we compared patients
with reduced eGFR (<30 ml/min) with healthy controls
(Figure 1b). To determine if these changes were solely
due to their association with progressive disease, we
compared plasma levels before and after renal trans-
plantation.11 Although plasma M-ﬁcolin and MAp19
levels fell signiﬁcantly posttransplantation in both IgAN
and a cohort of adult polycystic kidney disease, plasma
MASP-3 levels did not change (Figure 1c).We concludedIgAN
(n=323)
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CLINICAL RESEARCH NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severitythat M-ﬁcolin and MAp19 levels were inﬂuenced by
both IgAN and eGFR, whereas MASP-3 levels were
inﬂuenced only by IgAN.
MASP-3 Plasma Levels Are Associated With
IgAN Severity
To explore the signiﬁcance of the altered lectin
pathway levels in IgAN, we compared patients with
either stable or progressive disease. M-ﬁcolin, L-ﬁcolin,
MASP-1, and MAp19 did not differ between the
groups (Supplementary Figure S7); however, MASP-3
levels were reduced in patients with progressive dis-
ease (Figure 2a), including those with progressive dis-
ease despite immunosuppressive therapy (Figure 2b).
Given the demonstrated stability of MASP-3 serology
levels over time,31,36 we compared plasma levels
(sampled at recruitment) with the Oxford Classiﬁcation
of IgA Nephropathy22 scores from diagnostic renal bi-
opsies. Plasma MASP-3 levels were lower in the patienta
c
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430cohort with biopsy evidence of mesangial hyper-
cellularity (Figure 2c) and tubular atrophy (Figure 2d).
Plasma MAp19 levels were higher in patients with
segmental sclerosis (mean 576 vs. 539 ng/ml; difference
37; 95% CI: 2–73 ng/ml; P ¼ 0.040). We did not
identify associations between histology parameters and
M-ﬁcolin, L-ﬁcolin, or MASP-1 levels.
Glomerular Complement Deposition Is
Associated With Progressive IgAN
To understand the signiﬁcance of the association be-
tween MASP-3 levels and progressive IgAN, we
assessed complement deposition in our stable and
progressive cohorts (Figure 3). In progressive compared
with stable disease, there was proportionately greater
glomerular staining for C3b/iC3b/C3c (odds ratio [OR]:
5.66; 95% CI: 1.49–23.39; P ¼ 0.02), C3d (OR: 17.6;
95% CI: 3.01–89.97; P ¼ 0.001), C4d (OR: 8.32; 95% CI:
2.00–30.33; P ¼ 0.004), and C5b9 (OR: 12.14; 95%b
d
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Figure 3. Glomerular complement staining in IgA nephropathy (IgAN). (a) Representative images for complement C3b/iC3b/C3c, C3d, C4d, or
C5b9. The top row represents present (þ) and the bottom row represents negative () staining. Original magniﬁcation 400. Bar ¼ 100 mm. (b)
Proportion of cases with present (black) versus absent/uncertain (gray) glomerular staining in stable and progressive IgAN. P values derived
from the Fisher exact test.
NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severity CLINICAL RESEARCHCI: 1.95–61.35; P ¼ 0.004). Glomerular C5b-9 staining,
a marker of complement terminal pathway activation,
signiﬁcantly correlated with both glomerular C3b/iC3b/
C3c and C3d but not C4d staining (Table 2). There was
no correlation between glomerular C4d and either C3d
or C3b/iC3b/C3c.
Glomerular FHR5 Deposition Is Associated With
Progressive IgAN
We have previously shown levels of negative (fH) and
positive regulators (FHR1, FHR5) of the complement
alternative pathway associated with progressive
IgAN.11 In progressive disease, there was
more glomerular staining for FHR5 (OR: 13.4; 95%Table 2. Correlation of mesangial complement antigen intensity in IgA ne
Correlation coefﬁcient R values C3b/iC3b/C3c C3d C4d
C3b/iC3b/C3c – 0.45 (P ¼ 0.01) 0.31 (P ¼ 0.09) 0
C3d – 0.22 (P ¼ 0.20) 0
C4d –
C5b9
fH
FHR1
FHR5
A correlation of complement antigen-staining intensities in sections from the same biopsy, u
correlation. P values shown have been adjusted for multiple analyses to minimize the false
Yekutieli). fH, factor H; FHR1, factor H–related protein 1; FHR5, factor H–related protein 5.
Kidney International Reports (2018) 3, 426–438CI: 2.2–66.9; P ¼ 0.002) and a trend for greater FHR1
staining (Figure 4). In contrast, glomerular staining for
fH was signiﬁcantly reduced in progressive compared
with stable disease (OR: 0.10; 95% CI: 0.008–0.87;
P ¼ 0.04). Glomerular FHR5 staining correlated with
glomerular C3b/iC3b/C3c, C3d, and C5b-9 but not C4d
(Table 2). In aggregate, a heat map of the glomerular
staining data showed that the renal biopsies from pa-
tients with progressive disease had more staining for
C3b/iC3b/C3c, C3d, C4d, C5b9, and FHR5 than those
with stable disease (Figure 5). Interestingly, the com-
bination of FHR5 staining with negative fH staining
was signiﬁcantly more common in patients with pro-
gressive (15/18, 88.2%) versus stable (4/16, 25%)phropathy native renal biopsies
C5b9 fH FHR1 FHR5
.57 (P < 0.001) 0.06 (P ¼ 0.52) 0.28 (P ¼ 0.8) 0.64 (P < 0.001)
.53 (P ¼ 0.003) 0.29 (P ¼ 0.11) 0.11 (P ¼ 0.42) 0.68 (P < 0.001)
0.34 (P ¼ 0.08) 0.22 (P ¼ 0.19) 0.08 (P ¼ 0.45) 0.27 (P ¼ 0.12)
– 0.26 (P ¼ 0.14) 0.31 (P ¼ 0.09) 0.75 (P < 0.001)
– 0.33 (P ¼ 0.09) 0.16 (P ¼ 0.30)
– 0.31 (P ¼ 0.09)
–
sing the 0, 0.5, 1þ, 2þ, and 3þ scale. R values are calculated from Spearman’s rank
discovery rate (using the 2-stage linear step-up procedure of Benjamini, Krieger, and
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Figure 4. Glomerular staining for alternative pathway regulators in IgA nephropathy (IgAN). (a) Representative images for complement factor H
(fH), and factor H–related proteins 1 (FHR1) and 5 (FHR5). The top row represents positive staining (þ) and the bottom row represents negative
staining (). Original magniﬁcation 400. Bar ¼ 100 mm. (b) The proportion of cases with positive (black) versus absent/minimal (gray)
glomerular staining in stable and progressive IgAN. P values derived from the Fisher exact test.
CLINICAL RESEARCH NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severitydisease (OR: 15; 95% CI: 2.5–62.6; P ¼ 0.001). Only 1 of
14 (6.7%) stable patients had glomerular FHR1 staining
and negative fH staining compared with 9 of 19
(47.4%) in the progressive cohort (OR: 12.6; 95% CI:
1.7–146.4; P ¼ 0.02). Surplus renal biopsy tissue was
available from 1 patient with stable and 1 with pro-
gressive IgAN who had homozygous deletion of the
CFHR3 and 1 genes. Glomerular FHR1 staining was
negative in both cases, but glomerular C3b/iC3b/C3c,
C3d, C4d, C5b9, and FHR5 was detectable (Figure 5).
Surplus renal biopsy tissue was available from 3 pa-
tients with MBL deﬁciency: 1 with stable and 2 with
progressive disease (Figure 5). Glomerular C4d deposi-
tion was present in the 2 patients with progressive
disease but negative in the patient with stable disease.
Glomerular C3b/iC3b/C3c was detectable in all 3.
The IgAN cohort demonstrated a range of
tubular FHR1 staining prevalence and intensity432(Supplementary Figure S8). FHR1 staining was often
present and absent in adjacent tubule segments
(Supplementary Figure S8). Eleven patients showed no
tubular staining for FHR1, 7 had 1þ, 19 had 2þ, and 4
had tubular cell FHR1 staining of 3þ intensity. The
intensity of tubular cell FHR1 staining did not correlate
with proteinuria, glomerular ﬁltration, or the presence
of tubular atrophy at the time of biopsy. And there was
no correlation with disease severity. We did not have
access to stored plasma samples to quantify the circu-
lating FHR1 concentration at the time of biopsy.DISCUSSION
We observed increased circulating M-ﬁcolin, L-ﬁcolin,
MASP-1, and MAp19 levels in patients with IgAN.
Conversely MASP-3 levels were reduced and associated
with progressive disease. Renal impairment partiallyKidney International Reports (2018) 3, 426–438
IgAN severity CFHR3-1 copies MBL deﬁcient C3b/iC3b/C3c C3d C4d C5b9 fH FHR1 FHR5
Stable 2 No 0 0 0 0.5 0 0 0
Stable 2 No 0 0.5 0.5 1 0.5 0.5 0
Stable 2 No 0.5 1 0 0 1 0.5
Stable 1 No 0.5 1 0 0 0 0.5 0
Stable 2 No 0.5 0.5 0 0.5 0.5 0 0.5
Stable 2 No 0.5 0.5 0 1 0
Stable 1 No 0.5 0.5 0.5 1 0 0.5 0.5
Stable 2 No 0.5 1 0.5 2 0 0.5 1
Stable 1 No 0.5 0.5 1 0.5 0.5 0.5 0.5
Stable 1 No 0.5 1 1 0.5 0 1 1
Stable 2 No 0.5 0 1 0.5 1
Stable 1 No 1 0 0 3 0.5 0 2
Stable 2 Yes 1 0.5 1 1 2
Stable 2 No 1 0.5 0.5 0.5 1 0.5
Stable 2 No 1 0.5 1 1 0 0.5 1
Stable 0 No 1 1 1 2 1 0 2
Stable 2 No 1 0 2 0 1 0.5 0
Stable 2 No 2 0.5 0.5 0 1 0 0.5
Stable 2 No 0 0.5
Progressive 2 No 0.5 1 1
Progressive 2 No 0.5 1 1 1 0 2 1
Progressive 2 No 0.5 2 0.5 1 0 1 2
Progressive 2 No 0.5 1 1 2 0 0.5 2
Progressive 1 No 1 0.5 0
Progressive 1 No 1 1 0
Progressive 1 Yes 1 0.5 1 0.5 0 2 0.5
Progressive 2 No 1 0.5 1 0.5 0 2
Progressive 2 Yes 1 1 1 1 0.5 1 1
Progressive 1 No 1 1 1 0.5
Progressive 2 No 1 1 1 2 0 2 1
Progressive 2 No 1 1 1 2 0 0 1
Progressive 1 No 1 1 1 2 0.5 0 2
Progressive 0 No 1 1 2 2 0.5 0 2
Progressive 2 No 1 1 2 3 0 1 0
Progressive 1 No 2 0.5 0 1 2
Progressive 2 No 2 0.5 2 0 1 2
Progressive 1 No 2 2 1 2 0 0 3
Progressive 2 No 2 2 1 2 0 0.5 3
Progressive 2 No 2 2 1 3 0 0 3
Progressive 2 No 3 2 2 3 0 0 3
Progressive 2 No 3 1 1 3 0 0.5 3
Progressive 1 No 3 2 0.5 3 1 0 3
Glomerular staining score: 0 0.5 1 2 3
Figure 5. Complement glomerular deposition in IgA nephropathy (IgAN). Glomerular staining intensity scores from surplus native renal biopsy
tissue from patients with either stable or progressive IgAN. Each row represents information from a single patient. Staining intensity was
scored: 0, absent; 0.5, minimal; 1, mild; 2, moderate; 3, strong. Filled cells indicate insufﬁcient renal tissue to perform staining. Mannan-binding
lectin (MBL) deﬁciency was deﬁned as a plasma level of less than 100 ng/ml. CFHR3-1, complement factor H–related 3 and 1 genes; fH,
complement factor H; FHR1, factor H–related protein 1; FHR5, factor H–related protein 5.
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levels, because these levels changed signiﬁcantly
following renal transplantation. M-ﬁcolin is mainly
synthesized in monocytes and granulocytes,37 but
almost all of our patients had a normal white cell count.Kidney International Reports (2018) 3, 426–438Although MASP-3 showed a positive correlation with
alanine aminotransferase, we identiﬁed negative cor-
relations with MASP-3 levels and IgAN severity. We
therefore think it is unlikely that the M-ﬁcolin and
MASP-3 results are explained by confounding with433
CLINICAL RESEARCH NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severityleucocyte count and liver inﬂammation, respectively.
Furthermore, MBL,38 M-ﬁcolin,25 L-ﬁcolin,39 MASP-1,40
and MAp1932 are not acute-phase proteins. Circulating
MASP-3 levels did not correlate with proteinuria,
excluding this as a cause for the low levels, and there is
no clear genotype-phenotype correlation to explain the
variation in MASP-3 levels.41
How these changes relate to IgAN pathogenesis is
unclear. Increased MASP-142 and MAp1942 levels occur
in lupus nephritis, so these changes are not speciﬁc to
IgAN. Glomerular L-ﬁcolin and MASP1/3 staining
correlated with IgAN severity,20 but circulating L-ﬁco-
lin levels did not.20 In fact, reduced circulating L-ﬁcolin
levels have been reported in lupus nephritis,43 although
thiswas not replicated in a Japanese cohort,44 in addition
to reduced M-ﬁcolin levels.29 M-ﬁcolin35 and L-ﬁcolin45
are capable of triggering lectin pathway activation, and
MASP-1 is essential for MASP-2 and lectin complement
activation,46 so higher levels of these 3 components
could be associated with greater complement activation
within the kidney. The signiﬁcance of the raisedMAp19
is unclear. It has been shown to have a regulatory role on
lectin pathway activation in vitro,47 but the physiolog-
ical relevance of this is unknown.32
MASP-3 levels are lower in patients with systemic
lupus erythematosus with nephritis compared with
those without,42 so low MASP-3 levels are not speciﬁc
to IgAN. When MASP-3 binds to pattern-recognition
molecules, it can displace MASP-2 and MASP-1,48
and, because it does not lead to convertase forma-
tion,49 inhibit activation.48,50 Low levels of MASP-3
could be associated with increased complement acti-
vation. However, MASP-3 activates pro-factor D to
factor D,51 a requirement for C3-convertase forma-
tion.52 Whether or not glomerular activation of the
alternative pathway in either lupus nephritis or IgAN
directly inﬂuences MASP-3 levels is unknown.
We replicated the association between IgAN severity
and glomerular C3b/iC3b/C3c10 and C4d.20,21 Our data
also showed an association between progressive IgAN
and glomerular C3d and C5b9. Glomerular C4d did not
correlate with either C3b/iC3b/C3c or C5b9. This may
reﬂect technical limitations (e.g., sample size, staining
procedure), but also could be because the amount of
C4d, compared with C3 and C5b-9, will be lower after
glomerular complement activation. Previous studies
have identiﬁed glomerular C3 and C5b9 in most C4d-
positive and -negative cases, but did not record anti-
gen correlations.20,21
The correlation of glomerular FHR5 deposition with
progressive IgAN is a key ﬁnding of our study.
Glomerular FHR5 correlated with C3b/iC3b/C3c, C3d,
and C5b9 staining, as previously reported.53 In a434proteomic analysis, glomerular FHR5 was 1.79 times
more abundant in patients with progressive versus
stable IgAN.54 FHR5 antagonizes the ability of fH to
negatively regulate C3 activation.55,56 Consequently, it
was interesting that patients with progressive disease
had more cases of glomerular FHR5 staining in the
absence of fH. Notably, there are phenotypic similar-
ities between IgAN and familial C3 glomerulopathy
associated with mutant FHR5 proteins.57,58
Considering the genetic and serology associations
between IgAN and FHR1,11,12,59,60 it was surprising
that glomerular FHR1 was absent in more than 50% of
progressive IgAN biopsies. Unlike FHR5, glomerular
FHR1 did not correlate with other complement anti-
gens. This could be explained by differences in bind-
ing avidity of FHR1 and FHR5 to C3b, iC3b, and
C3dg.55 Nevertheless, our data indicate a more promi-
nent role for FHR5 than FHR1 in complement activation
in IgAN. Notably, 1 patient with progressive disease
was deﬁcient in FHR1.
The cause of tubular cell FHR1 staining is unclear. It
did not correlate with proteinuria at the time of biopsy.
It may result from changes to the tubular cell mem-
brane as a consequence of nephron loss or changes in
tubular ﬂuid characteristics, such as acidity, or tubular
epithelia or glycocalyx features.
Our complement staining data demonstrated the
pathogenic heterogeneity of IgAN. For example, the co-
deposition of FHR5, C3d, C3b/iC3b/C3c, and C5b9,
especially in the absence of fH, implies FHR5-
dependent fH deregulation and alternative pathway
activation, and glomerular co-deposition of C4d with
C3b/iC3b/C3c and C5b9 may reﬂect complement acti-
vation triggered by the lectin pathway. Interestingly,
all 4 biopsies from patients with progressive disease
and negative glomerular C4d had FHR5 staining.
Identifying and understanding this heterogeneity of
complement activity might be clinically important
because we now have the ability to target complement
activation at speciﬁc points in the activation sequence.
For example, OMS721, a monoclonal antibody targeting
MASP-2, was recently designated breakthrough ther-
apy status for IgAN treatment; Eculizumab, a C5 in-
hibitor, has been used in recurrent61 and
progressive62,63 IgAN; and factor D inhibitors are in
clinical trials for C3 glomerulopathy.64
Although our observations require conﬁrmation in
larger IgAN cohorts, our data indicate (Figure 6) that (i)
circulating MASP-3 is a potential biomarker of disease
severity in IgAN; and (ii) glomerular FHR5 staining of
diagnostic biopsies can identify those with severe
disease who are at risk of progression to renal
impairment.Kidney International Reports (2018) 3, 426–438
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Figure 6. Complement and IgA nephropathy. (a) Schematic diagram depicting lectin and alternative pathway complement activation. Lectin
pathway activation is triggered by the binding of pattern-recognition molecules (PRMs) to carbohydrate or acetyl molecular patterns. Alter-
native pathway activation happens through the spontaneous, constant generation of reactive forms of C3. Both pathways result in the gen-
eration of C3b. C3b can be proteolytically cleaved to iC3b and C3d by complement factor I in the presence of cofactors, such as complement
factor H. Similarly, C4b produced during lectin pathway activation can be cleaved to C4d. C3b generation can be rapidly ampliﬁed through an
ampliﬁcation loop. This results in the generation of large amounts of the opsonin C3b and can trigger complement C5 activation. This leads to
the generation of the anaphylatoxin C5a, and the membrane attack complex (C5b-9) through the terminal pathway. fH, factor H; fI, factor I; MAp,
MBL-associated protein; MASP, MBL-associated serine protease; MBL, mannose-binding lectin. (b) Complement proteins and severity of IgA
nephropathy. Within plasma, increased levels of FHR1,11,12 FHR5,11 and the FHR1:fH ratio11,12 associate with progressive IgAN. Conversely, we
found that reduced levels of MASP-3 associated with progressive disease. Within glomeruli, we replicated the association between increased
C4d12,20,21 and C3b/iC3b/C3c10 with IgAN severity, and we showed that increased glomerular C3d, C5b-9, and FHR5 associated with progressive
disease. The presence of FHR1 in the absence of fH was also more frequently seen in patients with progressive disease. FHR1, factor H–related
protein 1; FHR5, factor H–related protein 5. (Continued)
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SUPPLEMENTARY MATERIAL
Figure S1. Table of IgA nephropathy and healthy control
cohort characteristics.
Figure S2. Representative images of renal immuno-
histochemistry staining for complement pathway
antigens: C3b/iC3b/C3c, C3d, C4d, and C5b-9. Original
magniﬁcation 400. Bar ¼ 100 mm.436Figure S3. Representative images of renal immuno-
histochemistry staining for complement pathway
antigens: FHR1, FHR5, and fH. Original magni-
ﬁcation 400. Bar ¼ 100 mm.
Figure S4. Representative image of liver immuno-
histochemistry staining for fH. Original magni-
ﬁcation 400. Bar ¼ 100 mm.
Figure S5. Graphs showing the (a) correlation of plasma
MASP-3 levels and urine protein-creatinine ratio (PCR) in
patients (n ¼ 223) with IgA nephropathy (IgAN); (b) the
correlation of plasma M-ﬁcolin with white cell count (WCC)
in patients (n ¼ 108) with IgAN; and (c) the correlation
between mannan-binding lectin (MBL)-associated serine
protease (MASP)-3 with alanine aminotransferase (ALT) in
patients (n ¼ 108) with IgAN.
Figure S6. Graphs showing the correlation between
estimated glomerular ﬁltration rate (eGFR) and (a)
M-ﬁcolin, (b) mannan-binding lectin (MBL)-associated
protein (MAp) 19, (c) MBL-associated serine protease
(MASP)-3 levels, (d) L-ﬁcolin, and (e) MASP-1 levels.
Figure S7. Table of circulating lectin pathway protein levels
in stable and progressive IgA nephropathy.
Figure S8. Renal immunohistochemistry staining for
factor H–related protein 1 (FHR1) in IgA nephropathy.
Representative images of tubular staining intensity 3þ (a),
2þ (b), 1þ (c), and 0 (d–f). (f) Representative image from a
patient with complete FHR1 deﬁciency. Bar ¼ 100 mm.
Correlation of tubular FHR1 staining intensity with
estimated glomerular ﬁltration rate (eGFR, g) at the time of
biopsy, urine protein-creatinine ratio (UPCR) at the time of
biopsy (h), the presence (T1 or T2) or absence (T0) of tubularKidney International Reports (2018) 3, 426–438
NR Medjeral-Thomas et al.: MASP-3, FHR5, and IgA Nephropathy Severity CLINICAL RESEARCHatrophy from the biopsy report (i); and disease severity at
enrollment (j).Nocorrelations reachedstatistical signiﬁcance.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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